Cagrilintide/semaglutide

Cagrilintide/semaglutide
Combination of
CagrilintideAmylin receptor agonist
SemaglutideGLP-1 receptor agonist
Clinical data
Trade namesCagriSema

Cagrilintide/semaglutide, known as CagriSema, is a combination of cagrilintide, a dual amylin and calcitonin receptor agonist, and semaglutide, a GLP-1 agonist[1]. It has been proposed as a follow-on to semaglutide (alone) or tirzepatide in treatments for obesity and type II diabetes.[2]

Applications

CagriSema is under investigation to treat type 2 diabetes and obesity. Preliminary trial results found a greater weight loss compared to either semaglutide or cagrilintide alone. HbA1c was significantly improved compared to cagrilintide alone and non-significantly better than semaglutide alone.[3][4] In a Phase II trial, weight loss averaged -15.6 percent after 32 weeks, comparable in efficacy to tirzepatide.[5][6]

Trials

CagriSema entered Phase III clinical trials in 2023.[7]

REDEFINE 1

In June 2025, results were published in the New England Journal of Medicine on REDEFINE 1, a 68-week, double-blind, Phase III clinical trial enrolling 3,417 participants, testing weekly cagrilintide 2.4 mg and semaglutide 2.4 mg individually and together versus placebo in obese/overweight subjects with comorbidities. People treated with CagriSema lost 20.4% of their body weight over 68 weeks, versus 11.5% with cagrilintide 2.4 mg alone, 14.9% with semaglutide 2.4 mg alone, and 3.0% with placebo.[8][9]

REDEFINE 2

In June 2025, results were published in the New England Journal of Medicine on REDEFINE 2, a 68-week, double-blind, Phase III clinical trial enrolling 1,206 participants. REDEFINE 2 reported that obese or overweight adult patients with type 2 diabetes lost 13.7% of their weight over 68 weeks with Cagrilintide/semaglutide, compared with 3.1% with placebo.[10][9]

REDEFINE 5

In April 2026, results were published in The Lancet on REDEFINE 5, a 68-week, double-blind, phase 3a clinical trial enrolling 331 participants. The study findings report that participants in the CagriSema cohort had an estimated mean bodyweight change of -18.4%, versus -11.7% for participants in the semaglutide cohort.[11]

References

  1. ↑ Kollewe, Julia (2026-02-23). "Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is labelled 'obsolete'". The Guardian. ISSN 0261-3077. Retrieved 2026-02-24.
  2. ↑ Thompson, Bronwyn (2025-03-25). "Next-gen weight-loss drugs will be here within 12 months". New Atlas. Retrieved 2025-04-05.
  3. ↑ Enebo, Lone B; Berthelsen, Kasper K; Kankam, Martin; Lund, Michael T; Rubino, Domenica M; Satylganova, Altynai; Lau, David C W (May 2021). "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial". The Lancet. 397 (10286): 1736–1748. doi:10.1016/S0140-6736(21)00845-X. PMID 33894838. S2CID 233354744.
  4. ↑ Frias, Juan P; Deenadayalan, Srikanth; Erichsen, Lars; Knop, Filip K; Lingvay, Ildiko; Macura, Stanislava; Mathieu, Chantal; Pedersen, Sue D; Davies, Melanie (August 2023). "Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial". The Lancet. 402 (10403): 720–730. doi:10.1016/S0140-6736(23)01163-7. PMID 37364590. S2CID 259237278.
  5. ↑ Idris, Iskandar (July 2023). "Coadministration of the long-acting amylin analog cagrilintide plus semaglutide ( CagriSema ), resulted in significantly greater weight loss, along with improved measures of glucose control, in a short phase 2 trial of patients with type 2 diabetes". Diabetes, Obesity and Metabolism Now. 1 (7) e68. doi:10.1002/doi2.68. ISSN 2688-8939.
  6. ↑ Holst, Jens Juul; Jepsen, Sara Lind; Modvig, Ida (April 2022). "GLP-1 – Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy". Current Opinion in Pharmacology. 63 102189. doi:10.1016/j.coph.2022.102189. PMID 35231672.
  7. ↑ Jeon, Eonju; Lee, Ki Young; Kim, Kyoung-Kon (1 June 2023). "Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon". Journal of Obesity & Metabolic Syndrome. 32 (2): 106–120. doi:10.7570/jomes23032. ISSN 2508-7576. PMC 10327684. PMID 37349257.
  8. ↑ Garvey, W. Timothy; Blüher, Matthias; Contreras, Cynthia Karenina Osorto; Davies, Melanie J.; Lehmann, Eva Winning; Pietiläinen, Kirsi H.; Rubino, Domenica; Sbraccia, Paolo; Wadden, Thomas; Zeuthen, Niels; Wilding, John P. H. (2025). "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity". New England Journal of Medicine. 393 (7): 635–647. doi:10.1056/NEJMoa2502081. ISSN 0028-4793. PMID 40544433.
  9. 1 2 "News Details". Novo Nordisk. Retrieved 2025-06-25.
  10. ↑ Davies, Melanie J.; Bajaj, Harpreet S.; Broholm, Christa; Eliasen, Astrid; Garvey, W. Timothy; Roux, Carel W. le; Lingvay, Ildiko; Lyndgaard, Christian Bøge; Rosenstock, Julio; Pedersen, Sue D. (2025). "Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes". New England Journal of Medicine. 393 (7): 648–659. doi:10.1056/NEJMoa2502082. ISSN 0028-4793. PMID 40544432.
  11. ↑ Yamauchi, Toshimasa; Becker, Niels-Peter; Hagemann, Christoffer Andersen; Huang, Kuo-Chin; Kiyosue, Arihiro; Lim, Soo; Onishi, Yukiko; Kosuvaripalli, Ananda; Takano, Tomoko; Ishigaki, Yasushi (2026). "Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): A multicentre, randomised, active-controlled, phase 3a trial". The Lancet Diabetes & Endocrinology. 14 (6): 450–462. doi:10.1016/S2213-8587(25)00402-4. PMID 42009015.


This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.